Well, we have many advantages to using NK and CAR-NK.
First of all, it’s an allogeneic source. It means that you have ready-to-use cells in the near future that are frozen, and you can use them quite quickly for the patient in a particular situation.
The disadvantage is that, I will say that we are in an early stage of research and development, and we will require [more] proof...
Well, we have many advantages to using NK and CAR-NK.
First of all, it’s an allogeneic source. It means that you have ready-to-use cells in the near future that are frozen, and you can use them quite quickly for the patient in a particular situation.
The disadvantage is that, I will say that we are in an early stage of research and development, and we will require [more] proof. We know at least that it is safe, but we have to work on efficacy, look at the dose, look at the combination therapy, and is there any sort of maintenance.
So this R&D procedure will take some years. I think that CAR-T have many, many years on the road, and NK-cells will start.